Hepatology Center of Excellence

Supporting hepatology patients living with a rare condition

Orsini’s Hepatology Center of Excellence launched in 2024 with our first program for primary biliary cholangitis (PBC). Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Patient-Centered Care

Experience compassionate care that prioritizes patients and their families. Our team supports patients of all ages, from infants to the elderly, extending care to the entire care team.

Insurance Coverage

Secure treatment coverage with assistance navigating payer and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Hepatology Conditions Supported

Explore the rare hepatology conditions Orsini supports below or see All Hepatology Therapies available through Orsini.

About Primary Biliary Cholangitis (PBC)

PBC is a rare, chronic disease that impairs liver function; bile flow is reduced, and bile acids accumulate in the liver, elevating liver enzyme numbers to dangerous levels. The disease affects about one in 1,000 women over the age of 40 and is associated with fatigue, itching, poor appetite, weight loss and an increased risk of liver-related death.

PBC Therapies Supported

Full Name	Livdelzi^® (seladelpar)
Drug	Livdelzi
Manufacturer	Gilead Sciences, Inc.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA
Disease	Primary Biliary Cholangitis (PBC)
Therapeutic Area	Hepatology
Enrollment Form Link	Enrollment Form
Phone Number	888-263-8004
Fax Number	877-846-0402
Product Website	livdelzihcp.com/